Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.
Analyst Price Forecast Suggests 43.57% Upside
As of April 1, 2025, the average one-year price target for Eli Lilly and is $1,043.17/share. The forecasts range from a low of $808.00 to a high of $1,249.50. The average price target represents an increase of 43.57% from its latest reported closing price of $726.60 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Eli Lilly and is 37,840MM, a decrease of 15.99%. The projected annual non-GAAP EPS is 15.45.
What is the Fund Sentiment?
There are 5,523 funds or institutions reporting positions in Eli Lilly and. This is an increase of 274 owner(s) or 5.22% in the last quarter. Average portfolio weight of all funds dedicated to LLY is 1.06%, an increase of 4.41%. Total shares owned by institutions increased in the last three months by 3.13% to 904,196K shares. 
The put/call ratio of LLY is 1.01, indicating a bearish outlook.
What are Other Shareholders Doing?
Lilly Endowment holds 96,892K shares representing 10.79% ownership of the company. No change in the last quarter.
Pnc Financial Services Group holds 51,303K shares representing 5.71% ownership of the company. In its prior filing, the firm reported owning 51,361K shares , representing a decrease of 0.11%. The firm decreased its portfolio allocation in LLY by 8.83% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 26,769K shares representing 2.98% ownership of the company. In its prior filing, the firm reported owning 27,115K shares , representing a decrease of 1.29%. The firm decreased its portfolio allocation in LLY by 15.22% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 21,329K shares representing 2.38% ownership of the company. In its prior filing, the firm reported owning 20,662K shares , representing an increase of 3.13%. The firm decreased its portfolio allocation in LLY by 14.90% over the last quarter.
Price T Rowe Associates holds 20,864K shares representing 2.32% ownership of the company. In its prior filing, the firm reported owning 20,930K shares , representing a decrease of 0.32%. The firm decreased its portfolio allocation in LLY by 13.03% over the last quarter.
Lilly Background Information
(This description is provided by the company.)
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
